Pancreatic
cancer often does not cause symptoms, so it is diagnosed late,
metastasizes earlier than other cancer and rapidly becomes resistant to
chemotherapy, making it one of the most difficult types of the disease
to treat.
Researchers have found schizophrenia drugs
were effective at slowing the growth of pancreatic tumors and impeding
their ability to prolifierate, according to a study
published in the journal Gastroenterology.
Pancreatic cancer accounts for about 3 percent of cancer cases in the United States, but 7 percent of cancer deaths,
according to the American Cancer Society.
The organization says that this year, about 53,070 people are expected
to be diagnosed with the disease, and roughly 41,780 will die of it.
Pancreatic cancer is often discovered at much later stages than other forms of the disease, and so is more difficult to treat.
To find new ways of treatment, researchers at
several institutions took on a large analysis of genetic activity among
pancreatic cancer patients, finding the dopamine receptor DRD2 was much
more active in the cancer cells of patients.
"We leveraged quantitative and computational
biology approaches that we have established in order to identify genes
that may play a central role in several pancreatic cancer-relevant
signaling pathways among almost 3,000 genes that exhibited abnormally
high or low activities" Yasser Riazalhosseini, a researcher at McGill
University and co-leader of the study, said in a
press release.
For the study, the researchers first tested
the effects of the antipsychotic drug pimozide against pancreatic cancer
cell lines, finding it substantially slowed the growth and mobility of
the cancer cells.
The researchers then implanted the cells in
mice, allowing them to grow into tumors before treating them with
haloperidol, a dopamine antagonist used with schizophrenia patients.
Although the mice still developed cancer from the implants, they
developed smaller tumors and had fewer metastases than mice not treated
with the drug.
"We do not know yet whether haloperidol or
related medications have the same effect in pancreatic cancer patients
as they have in tumor cells and mice," said Jörg Hoheisel, a researcher
at the German Cancer Research Center, adding the the next step would be
to test the drugs in human pancreatic cancer patients.
Comments
Post a Comment